New combo shows promise against tough skin cancer

NCT ID NCT05309421

Ongoing Disease control Sponsor: Evaxion Biotech A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether adding an experimental drug (EVX-01) to standard immunotherapy (pembrolizumab) can shrink tumors better than pembrolizumab alone in people with advanced melanoma that cannot be removed by surgery. Seventeen adults who have never received checkpoint inhibitors are being treated and followed for up to two years. The main goal is to see if the combination improves the overall response rate compared to historical data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EVX-01 (investigational drug) plus pembrolizumab (Keytruda)
What this could lead to: If successful, this combination could improve tumor shrinkage and delay cancer progression in people with advanced melanoma who haven't had checkpoint inhibitor therapy.
What could go wrong: This is a small, early-phase trial with only 17 participants and no comparison group. Results may not apply to all patients, and the combination could cause added side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA STAGE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA STAGE IV UNRESECTABLE MELANOMA

Contacts and locations

Locations

Divisione di Oncologia Medica del Melanoma

Milan, Italy
Instituto Nazionale Tumori IRCCS Fondazione

Naples, Italy
Melanoma Institute Australia

Wollstonecraft, New South Wales, 2065, Australia
One Clinical Research

Nedlands, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.